Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology

Share:

ICON
plc
(NASDAQ:ICLR), a global provider of drug development and
commercialisation solutions and services, today announced it has signed
an agreement with AG Mednet to use Judi, a comprehensive electronic
endpoint adjudication system to manage workflow and ensure data quality,
for enhanced endpoint event adjudication services. Judi, an integrated,
cloud-based SaaS tool, provides a level of flexibility that enables the
implementation of the most complex endpoint and adverse event processes,
delivering fewer queries, higher transparency and increased quality for
clients.

ICON is a leader in endpoint adjudication and has already successfully
deployed Judi for thousands of events across multiple therapeutic areas
including oncology, obesity and diabetes. It has established
relationships with over 400 experts and key opinion leaders around the
world and works collegially with multiple partners and Academic Research
Organizations in support of Data Monitoring Committees and event
adjudication.

"Judi provides a purpose built solution for endpoint adjudication that
enables efficient database set-up, data extraction and manages workflow
effectively," said Craig McLendon, Senior Director, Adjudication and
Data Monitoring Committees Management, ICON. "Combining ICON's
adjudication experience and expertise with innovative technology from AG
Mednet enables us provide a world class service for even the most
demanding endpoint adjudication projects".

"We developed Judi from the ground up, incorporating a level of
flexibility that enables quality and accuracy in reported data from
studies. ICON has been an ideal partner in ensuring that both the
development and the implementation of Judi meet the technical and
clinical needs of investigator sites, CRO reviewers, adjudicators and
clinical event committees," said Abraham Gutman, president and CEO, AG
Mednet.

ICON provides customised, efficient, stream-lined, high-quality,
regulatory compliant solutions for projects of all sizes and all
therapeutic areas.

About ICON plc
ICON plc is a global provider of outsourced
drug development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and public
health organisations. The company specializes in the strategic
development, management and analysis of programs that support clinical
development from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees.
Further information is available at www.iconplc.com/eas

About AG Mednet
AG Mednet is the leading quality compliance
partner for image data submission and collection, as well as endpoint
adjudication and adverse event adjudication workflows. The company is a
leading proponent of zero-delay clinical trials, and has supported more
than 1,000 global clinical trials. Dozens of adjudication protocols are
managed by sponsors and CROs using Judi. More than 55,000 registered
users across thousands of investigator sites in more than 80 countries
use AG Mednet to submit more than 14,000,000 images per month and
adjudicate hundreds of events in projects sponsored by each of the
world's top 20 pharmaceutical, biotech and medical device companies.

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at 
http://www.sec.gov.

ICON/ICLR-G

View Comments and Join the Discussion!